Uveitis

Ophthalmology·MeSH: Uveitis, Intermediate

Prevalence

30.0 / 100K

14 drugs in development·11 companies·2 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
abrilada	PFIZER INC (PFE)
Hadlima (SB5)	Organon & Co. (OGN)
iluvien	ALIMERA SCIENCES INC (ALIM)
ILUVIEN	ANI PHARMACEUTICALS INC (ANIP)
ozurdex	AbbVie Inc. (ABBV)
triamcinolone acetonide	Teva Pharmaceutical Industries Limited (TEVA)
XIPERE	Clearside Biomedical, Inc. (CLSDQ)
YUTIQ	ANI PHARMACEUTICALS INC (ANIP)

Phase 3(2)

Drug	Company
adalimumab	ELI LILLY & Co (LLY)
Yutiq 0.18 MG Drug Implant	ANI PHARMACEUTICALS INC (ANIP)

Preclinical(2)

Drug	Company
h-n08	HARROW, INC. (IMMY)
vt-1908	Vyome Holdings, Inc (HIND)

Unknown(1)

Drug	Company
fluocinolone acetonide intravitreal implant	ANI PHARMACEUTICALS INC (ANIP)

Phase 1/Phase 2(1)

Drug	Company
regn7041	REGENERON PHARMACEUTICALS, INC. (REGN)

BioSniper tracks 14 drugs in development for Uveitis across 11 companies.

There are 2 clinical trials targeting Uveitis tracked by BioSniper.

The estimated prevalence of Uveitis is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.